Held
HNGE · Hinge Health, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 10 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-06-18 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-10 and is not part of the scored record.
Current thesis
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
Kill line
A weekly close below $58 forfeits the June breakout above the $62.18 prior ATH and drops the tape back into its nine-month range; secondary breaks are the digital-MSK theme rolling to saturated or the ~2026-08-04 Q2 print landing under the raised $200–202M revenue floor.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for HNGE —
As of 10 September 2026, the latest FrontierPicks analysis for Hinge Health, Inc. (HNGE): Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
Kill line: A weekly close below $58 forfeits the June breakout above the $62.18 prior ATH and drops the tape back into its nine-month range; secondary breaks are the digital-MSK theme rolling to saturated or the ~2026-08-04 Q2 print landing under the raised $200–202M revenue floor.
Current Thesis
Hinge Health’s profitable digital musculoskeletal care story supports a continuation thesis, settled by a weekly close above the August 27 high of $92.85 before a weekly close below the August 28 reference close of $87.35. The adjusted daily market close was $91.31 on 2026-09-09, leaving that confirmation unresolved.
Stifel’s 2026-09-08 price-target increase to $115 remains the latest identified analyst development. The September 9 close does not establish that this renewed attention has produced a breakout. The target is Stifel’s valuation opinion, not a measured company outcome. Stifel report
The inference is that the narrative is maturing — the 2026-08-04 earnings release now has a September 8 analyst extension, while the September 9 close remains below the August high. A fresh company guidance increase accompanied by a weekly close above $92.85 would contradict that classification.
Bullish and bearish views on Hinge Health, Inc.
The model's bull view on Hinge Health, Inc. (HNGE), in brief: Growth accompanies cash generation. The 2026-08-04 release reported second-quarter revenue of $212.8 million, up 53% year over year, and free cash flow of $99.6 million. These measured results support the operating premise behind the rerating. Company results Management supplied… The bear view: Sponsor transactions document selling. The SEC Form 4 filed on 2026-08-27, accession 0001193125-26-371548, records Bessemer-affiliated entities selling Class A shares on August 25 and August 26. The filing establishes supply; it does not establish the sellers’ motivation or… Both cases follow in full.
Bull Case
- Growth accompanies cash generation. The 2026-08-04 release reported second-quarter revenue of $212.8 million, up 53% year over year, and free cash flow of $99.6 million. These measured results support the operating premise behind the rerating. Company results
- Management supplied a measurable hurdle. On 2026-08-04, Hinge guided third-quarter revenue to $223–225 million and full-year revenue to $856–860 million. Third-quarter revenue below $223 million would contradict the growth premise; the ranges are management forecasts. Company outlook
- Analyst support remains active. Stifel raised its price target to $115 on 2026-09-08, according to Investing.com. This documents a continuing valuation revision, but price confirmation still requires the weekly breakout specified above. Stifel report
Bear Case
- Sponsor transactions document selling. The SEC Form 4 filed on 2026-08-27, accession 0001193125-26-371548, records Bessemer-affiliated entities selling Class A shares on August 25 and August 26. The filing establishes supply; it does not establish the sellers’ motivation or subsequent demand.
- Authorization does not establish demand. Hinge’s 2026-08-04 release disclosed $300 million available for future repurchases as of July 29. The program does not obligate purchases, so the authorization cannot establish company demand during September. Repurchase disclosure
- Attention has incomplete price confirmation. The September 8 Stifel revision was followed by the adjusted September 9 close of $91.31, below the market’s August 27 high of $92.85. This observation is insufficient to establish either distribution or expanding participation. Analyst revision
Setup & Price Structure
The adjusted market series dated 2026-09-09 records a $91.31 daily close, a three-month price increase of 47.1%, and a close 1.7% below the $92.85 trailing-year high. The advance is measured; sustained acceptance above that high is not yet demonstrated by the supplied close.
The August 27 high of $92.85 defines the continuation hurdle. The August 28 close of $87.35 defines the thesis-break reference. That lower reference is a dated market observation, not evidence of a repeatedly tested support zone; a weekly close below $87.35 before confirmation ends this continuation case.
The available September 9 evidence does not provide a moving-average level, current ownership flows or an updated short-interest observation. The August sponsor filing and September analyst revision therefore support a description of selling and attention, not a conclusion that the stock is crowded.
Catalyst Calendar (next 30 days)
- 2026-09-30 — Third-quarter reporting period ends. This closes the measurement period for management’s $223–225 million revenue outlook issued on 2026-08-04. Quarter-end is an accounting milestone, not a scheduled results announcement. Company outlook
As of 2026-09-10, no company-confirmed earnings or conference date inside the next 30 days was established from the available investor-relations calendar. The third-quarter results date remains unconfirmed; a sector conference without confirmed Hinge participation is not a company catalyst. Company events calendar
What Would Change Our Mind
Loss of the August 28 reference would break the continuation structure: a weekly close below $87.35 before a weekly close above $92.85 invalidates the published price thesis. Conversely, a weekly close above the August 27 high of $92.85 first would satisfy its defined continuation outcome.
Operating evidence has a separate test. Reported third-quarter revenue below the $223 million guidance floor issued on 2026-08-04 would undermine the growth premise even if the price hurdle had already been reached. Revenue guidance
Correlation Notes
FrontierPicks’ Managed care & health services coverage trail classified the group as saturated on 2026-08-04, 2026-09-06 and 2026-09-10. The September 10 comparison group includes CNC, HUM, OSCR and AVAH. These are editorial theme observations, not measured return correlations or fund-flow data.
The group classification raises the evidentiary bar for attributing Hinge’s September 9 three-month advance of 47.1% to broad sector participation. No synchronized peer-return series is supplied, so the evidence supports no numerical correlation claim. The single-company continuation case remains falsifiable at the dated market levels above regardless of the group label.
Notes
- Dual-class structure: Class B converts into Class A before insider open-market sales, so a Form 4 shows a conversion leg ahead of the sale line.
- Form 4 transaction code F is share withholding for RSU tax obligations, not a discretionary sale; code S is the open-market line.
- Rule 10b5-1 plans are active for executives and sponsor-affiliated funds, so Form 4s arrive on a schedule rather than in response to news.
- Guided operating margins are non-GAAP; GAAP figures are disclosed separately and ran materially lower before the Q2 2026 crossover.
- Float was 45.39M against 77.38M shares outstanding, with 13.73% of float short at the last reported update.
- Guided diluted share count of 85-87M sits above shares outstanding, so per-share comparisons drift as PSUs and RSUs settle.
Related · shared themes
HUM
Humana Inc.
Humana's Medicare Advantage margin reset supports continuation above the $409.42 adjusted reference high before a daily close below $383. Bernstein maintained its $425 analyst target on 2026-09-09, while October Star Ratings leave the 2028 operating objective unresolved.
OSCR
Oscar Health, Inc.
Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the specified growth framework also ends the case.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 invalidates the case.
CXW
CoreCivic, Inc.
DHS is buying CoreCivic's detention real estate outright — $2.2B gross for four facilities, about $307k/bed — while CoreCivic keeps operating them; proceeds funded $608.5M of debt repayment and a $500M buyback expansion (2026-08-05 release). Shares closed 2026-09-04 at a 52-week high of $34.71 with RSI 56.4, and no company-dated catalyst falls inside the next 30 days.
See also · stocks to watch